Netflix tracking ahead of Q2 ad tier estimate, says JPMorgan » 05:28 NFLX
Perspective Therapeutics price target raised to $2.20 from $1.50 at JonesResearch » 04:51 CATX
This is an interesting case study HUMA. I am 90% sure these guys had insider selling which led me to stay away during a recent FDA read out which I am 75% sure was positive. And I'm 40% sure the stk really didn't move on the news. and now I am 100% sure someone is trying to change the narrative...
Humacyte director buys $667.5K in common stock » 19:54 HUMA
This afternoon we have to go through this//////////
Perspective Therapeutics price target raised to $2.20 from $1.50 at JonesResearch » 04:51 CATX
This is an interesting case study HUMA. I am 90% sure these guys had insider selling which led me to stay away during a recent FDA read out which I am 75% sure was positive. And I'm 40% sure the stk really didn't move on the news. and now I am 100% sure someone is trying to change the narrative...
Humacyte director buys $667.5K in common stock » 19:54 HUMA
This afternoon we have to go through this//////////

4:00 PM 05/15/24